Literature DB >> 12940844

MR imaging of the brain in patients with hepatic form of Wilson's disease.

D Kozić1, M Svetel, B Petrović, N Dragasević, R Semnic, V S Kostić.   

Abstract

The aim of this study was to detect the sites and frequency of possible lesions by brain magnetic resonance imaging (MRI; 1,5T) in a group of 16 neurologically asymptomatic patients with hepatic form of Wilson's disease (WD; seven untreated and nine under treatment). Abnormal MR findings of the brain were found in 75% of patients. Lesions in brain parenchyma were detected in all untreated, drug-naive patients and in 44% of treated patients. Abnormal signal in globus pallidus, putamen, and caudate nucleus was revealed in 86, 71 and 71% of treated and in 33, 33 and 22% of untreated patients, respectively. In five of eight patients with putaminal pathology (62.5%) and in four of seven patients with caudate nuclei involvement (57%), only proton density 2-weighted sequence (PDW) exhibited sensitivity for lesion detection, with both T1W and long echo T2W sequences being insensitive. This superiority of PDW sequence was even more pronounced in the group of untreated patients in whom 80% of putaminal pathology was visible exclusively on this sequence. The lower frequency of lesions in the group of treated in comparison with untreated patients indicated that they might be reversible in the course of chronic chelating therapy.

Entities:  

Mesh:

Year:  2003        PMID: 12940844     DOI: 10.1046/j.1468-1331.2003.00661.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  17 in total

1.  Early MRI findings in acquired hepatocerebral degeneration.

Authors:  Roberto Erro; Carmine Vitale; Marina Picillo; Paolo Barone; Maria Teresa Pellecchia
Journal:  Neurol Sci       Date:  2012-04-15       Impact factor: 3.307

2.  Wilson disease: Canadian perspectives on presentation and outcomes from an adult ambulatory setting.

Authors:  A Moores; Susan Fox; Anthony Lang; Gideon M Hirschfield
Journal:  Can J Gastroenterol       Date:  2012-06       Impact factor: 3.522

3.  Interhemispheric asymmetry of brain diffusivity in normal individuals: a diffusion-weighted MR imaging study.

Authors:  Andrew J Fabiano; Mark A Horsfield; Rohit Bakshi
Journal:  AJNR Am J Neuroradiol       Date:  2005-05       Impact factor: 3.825

Review 4.  Neurologic impairment in Wilson disease.

Authors:  Petr Dusek; Tomasz Litwin; Anna Członkowska
Journal:  Ann Transl Med       Date:  2019-04

Review 5.  Wilson disease.

Authors:  Anna Członkowska; Tomasz Litwin; Petr Dusek; Peter Ferenci; Svetlana Lutsenko; Valentina Medici; Janusz K Rybakowski; Karl Heinz Weiss; Michael L Schilsky
Journal:  Nat Rev Dis Primers       Date:  2018-09-06       Impact factor: 52.329

6.  MR imaging of the brain in Wilson disease of childhood: findings before and after treatment with clinical correlation.

Authors:  T J Kim; I O Kim; W S Kim; J E Cheon; S G Moon; J W Kwon; J K Seo; K M Yeon
Journal:  AJNR Am J Neuroradiol       Date:  2006 Jun-Jul       Impact factor: 3.825

7.  Wilson's disease patient with iron metabolism discharge barriers: A case report.

Authors:  Guoen Cai; Xinming Huang; Qinyong Ye; Wenting Xiong; Qing Duan
Journal:  Exp Ther Med       Date:  2016-11-24       Impact factor: 2.447

8.  Structural and Functional Changes Are Related to Cognitive Status in Wilson's Disease.

Authors:  Sheng Hu; Chunsheng Xu; Ting Dong; Hongli Wu; Yi Wang; Anqin Wang; Hongxing Kan; Chuanfu Li
Journal:  Front Hum Neurosci       Date:  2021-02-25       Impact factor: 3.169

9.  Basal ganglia-orbitofrontal circuits are associated with prospective memory deficits in Wilson's disease.

Authors:  Sheng Hu; ChunSheng Xu; Yi Wang; Ting Dong; Hongli Wu; Anqin Wang; Chuanfu Li; BenSheng Qiu
Journal:  Brain Imaging Behav       Date:  2021-07-23       Impact factor: 3.978

10.  The effect of gender on brain MRI pathology in Wilson's disease.

Authors:  T Litwin; G Gromadzka; A Członkowska; M Gołębiowski; R Poniatowska
Journal:  Metab Brain Dis       Date:  2013-01-15       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.